Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | PPARG | P37231 | 1/20 | 0.65 |
| ▸ | HIF1A | Q16665 | 6/20 | 0.64 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.51 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.51 |
| ▸ | PDE4A | P27815 | 1/20 | 0.50 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.50 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.50 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.49 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.49 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.49 |
| ▸ | CDC42 | P60953 | 1/20 | 0.49 |
| ▸ | RAC1 | P63000 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14156990 | 0.90 | HIF1A (0.57) | MAPTKMT2AMEN1CYP3A4PPARG | |
| SCHEMBL23564661 | 0.90 | HIF1A (0.79) | MAPTKMT2AMEN1CYP3A4PPARG | |
| SCHEMBL30511127 | 0.90 | HIF1A (0.79) | MAPTKMT2AMEN1CYP3A4PPARG | |
| SCHEMBL23523355 | 0.90 | HIF1A (0.79) | MAPTKMT2AMEN1CYP3A4PPARG | |
| SCHEMBL3064489 | 0.88 | CYP3A4 (0.61) | MAPTKMT2AMEN1CYP3A4PPARG | |
| SCHEMBL12255051 | 0.86 | MEN1 (0.56) | MAPTKMT2AMEN1CYP3A4PPARG | |
| SCHEMBL14519861 | 0.83 | NPC1 (0.60) | MAPTKMT2AMEN1CYP3A4HIF1A | |
| SCHEMBL9732890 | 0.82 | NPC1 (0.58) | MAPTKMT2AMEN1CYP3A4HIF1A | |
| SCHEMBL13100433 | 0.81 | MEN1 (0.54) | MAPTKMT2AMEN1CYP3A4PPARG | |
| SCHEMBL1922400 | 0.81 | NPC1 (0.57) | MAPTKMT2AMEN1CYP3A4HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212989-A1 | THERAPEUTIC METHODS AND COMPOSITIONS INVOLVING ISOFLAVONES | NOVOGEN RESEARCH PTY LTD (AU) | 2011-09-01 | — | — | US | disclosed |
| US-7915308-B2 | Therapeutic methods and compositions involving isoflavones | NOVOGEN RESEARCH PTY LTD (AU) | 2011-03-29 | — | — | US | disclosed |
| US-7915308-B2 | Therapeutic methods and compositions involving isoflavones | NOVOGEN RESEARCH PTY LTD (AU) | 2011-03-29 | — | — | US | disclosed |
| US-20080287528-A1 | THERAPEUTIC METHODS AND COMPOSITIONS INVOLVING ISOFLAVONES | NOVOGEN RESEARCH PTY LIMITED (AU) | 2008-11-20 | — | — | US | disclosed |
| US-20080287528-A1 | THERAPEUTIC METHODS AND COMPOSITIONS INVOLVING ISOFLAVONES | NOVOGEN RESEARCH PTY LIMITED (AU) | 2008-11-20 | — | — | US | disclosed |
| US-7419998-B2 | Therapeutic methods and compositions involving isoflavones | NOVOGEN RESEARCH PTY LTD (AU) | 2008-09-02 | — | — | US | disclosed |
| US-7419998-B2 | Therapeutic methods and compositions involving isoflavones | NOVOGEN RESEARCH PTY LTD (AU) | 2008-09-02 | — | — | US | disclosed |
| EP-1927352-A2 | Therapeutic methods and compositions involving isoflavones | Novogen Research Pty. Ltd. (AU) | 2008-06-04 | — | — | EP | disclosed |
| US-7202273-B2 | Therapeutic methods and compositions involving isoflavones | NOVOGEN RESEARCH PTY LTD (AU) | 2007-04-10 | — | — | US | disclosed |
| US-7202273-B2 | Therapeutic methods and compositions involving isoflavones | NOVOGEN RESEARCH PTY LTD (AU) | 2007-04-10 | — | — | US | disclosed |
| US-20060286150-A1 | Therapeutic methods and compositions involving isoflavones | NOVOGEN RESEARCH PTY LTD. | 2006-12-21 | — | — | US | disclosed |
| US-20050131047-A1 | Therapeutic methods and compositions involving isoflavones | NOVOGEN RESEARCH PTY LIMITED (AU) | 2005-06-16 | — | — | US | disclosed |
| US-20050059616-A1 | Therapeutic methods and compositions involving isoflavones | KELLY GRAHAM EDMUND (AU) | 2005-03-17 | — | — | US | disclosed |
| EP-0954302-A4 | THERAPEUTIC METHODS AND COMPOSITIONS INVOLVING ISOFLAVONES | NOVOGEN RES PTY LTD (AU) | 2005-03-02 | — | — | EP | disclosed |
| US-6649648-B1 | Administering 1-chroman, 1-thiochroman or quinoline derivative as anticarcinogenic or antimetastasis agent | NOVOGEN RESEARCH PTY LIMITED (AU) | 2003-11-18 | — | — | US | disclosed |
| US-20030018060-A1 | Therapeutic methods and compositions involving isoflavones | NOVOGEN RESEARCH PTY LIMITED (AU) | 2003-01-23 | — | — | US | disclosed |
| US-20020198248-A1 | Therapeutic methods and compositions involving isoflavones | NOVOGEN RESEARCH PTY LIMITED (AU) | 2002-12-26 | — | — | US | disclosed |
| EP-0954302-A1 | THERAPEUTIC METHODS AND COMPOSITIONS INVOLVING ISOFLAVONES | Novogen Research Pty. Ltd. (AU) | 1999-11-10 | — | — | EP | disclosed |
| WO-1998008503-A1 | THERAPEUTIC METHODS AND COMPOSITIONS INVOLVING ISOFLAVONES | NOVOGEN RESEARCH PTY. LTD. (AU) | 1998-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018060-A1 | Therapeutic methods and compositions involving isoflavones | NR1H2, ESRRA, NR1H3 | MAPT 4537/4885KMT2A 3229/4885MEN1 4228/4885 |
| US-20110212989-A1 | THERAPEUTIC METHODS AND COMPOSITIONS INVOLVING ISOFLAVONES | C1R, C1S, ESRRA | MAPT 3988/4885KMT2A 3505/4885MEN1 3513/4885 |
| US-20060286150-A1 | Therapeutic methods and compositions involving isoflavones | C1R, ESRRA, ESRRB | MAPT 3933/4885KMT2A 3311/4885MEN1 3303/4885 |
| US-20020198248-A1 | Therapeutic methods and compositions involving isoflavones | ESRRA, NR1H2, NR1H3 | MAPT 4193/4885KMT2A 2947/4885MEN1 3811/4885 |
| US-20080287528-A1 | THERAPEUTIC METHODS AND COMPOSITIONS INVOLVING ISOFLAVONES | C1R, ESRRA, ESRRB | MAPT 3948/4885KMT2A 3320/4885MEN1 3266/4885 |
| US-20050131047-A1 | Therapeutic methods and compositions involving isoflavones | C1R, ESRRA, ESRRB | MAPT 3840/4885KMT2A 3330/4885MEN1 3316/4885 |
| US-20050059616-A1 | Therapeutic methods and compositions involving isoflavones | C1R, ESRRA, ESRRB | MAPT 3989/4885KMT2A 3361/4885MEN1 3483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.